Published in Cancer Weekly, December 21st, 2004
"Despite treatment, a large number of women with ovarian cancer eventually relapse and die of [ovarian cancer]. Hence, recurrent ovarian cancer continues to be a therapeutic dilemma, possibly a result of the emergence of drug resistance during relapse," said Z.E. Selvanayagam and colleagues, University of Hong Kong, Prince of Wales Hospital.
"Recent advances in expression genomics enable global transcript analysis that leads to molecular classification of cancers and prediction of outcome and treatment response," they...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.